Selected research
Industry Research
Binge Eating Disorder Drug Industry Research Report 2026
Market perspective
The global Binge Eating Disorder Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Binge Eating Disorder Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Binge Eating Disorder Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Binge Eating Disorder Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Binge Eating Disorder Drug include Novo Nordisk, Roche, Sunovion Pharmaceuticals, Opiant Pharmaceuticals, Omeros Corp, Heptares and Chronos Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Binge Eating Disorder Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Binge Eating Disorder Drug Market by Company
Novo Nordisk
Roche
Sunovion Pharmaceuticals
Opiant Pharmaceuticals
Omeros Corp
Heptares
Chronos Therapeutics
Binge Eating Disorder Drug Segment by Type
Anti-obesity Medications
Anticonvulsants
Antidepressants
Binge Eating Disorder Drug Segment by Application
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
Binge Eating Disorder Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Binge Eating Disorder Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Binge Eating Disorder Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Binge Eating Disorder Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Binge Eating Disorder Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Binge Eating Disorder Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Binge Eating Disorder Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Anti-obesity Medications
- Anticonvulsants
- Antidepressants
Applications
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
Companies covered
- Novo Nordisk
- Roche
- Sunovion Pharmaceuticals
- Opiant Pharmaceuticals
- Omeros Corp
- Heptares
- Chronos Therapeutics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Binge Eating Disorder Drug Market Size (2021-2032)
- 2.2.2 Global Binge Eating Disorder Drug Sales (2021-2032)
- 2.2.3 Global Binge Eating Disorder Drug Market Average Price (2021-2032)
- 2.3 Binge Eating Disorder Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Anti-obesity Medications
- 2.3.3 Anticonvulsants
- 2.3.4 Antidepressants
- 2.4 Binge Eating Disorder Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Retail Pharmacies
- 2.4.3 Online Pharmacies
- 2.4.4 Hospital Pharmacies
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Binge Eating Disorder Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Binge Eating Disorder Drug Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Binge Eating Disorder Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Binge Eating Disorder Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Binge Eating Disorder Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Binge Eating Disorder Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Binge Eating Disorder Drug, Product Type & Application
- 3.8 Global Manufacturers of Binge Eating Disorder Drug, Established Date
- 3.9 Global Binge Eating Disorder Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novo Nordisk
- 4.1.1 Novo Nordisk Company Information
- 4.1.2 Novo Nordisk Business Overview
- 4.1.3 Novo Nordisk Binge Eating Disorder Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novo Nordisk Binge Eating Disorder Drug Product Portfolio
- 4.1.5 Novo Nordisk Recent Developments
- 4.2 Roche
- 4.2.1 Roche Company Information
- 4.2.2 Roche Business Overview
- 4.2.3 Roche Binge Eating Disorder Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Roche Binge Eating Disorder Drug Product Portfolio
- 4.2.5 Roche Recent Developments
- 4.3 Sunovion Pharmaceuticals
- 4.3.1 Sunovion Pharmaceuticals Company Information
- 4.3.2 Sunovion Pharmaceuticals Business Overview
- 4.3.3 Sunovion Pharmaceuticals Binge Eating Disorder Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sunovion Pharmaceuticals Binge Eating Disorder Drug Product Portfolio
- 4.3.5 Sunovion Pharmaceuticals Recent Developments
- 4.4 Opiant Pharmaceuticals
- 4.4.1 Opiant Pharmaceuticals Company Information
- 4.4.2 Opiant Pharmaceuticals Business Overview
- 4.4.3 Opiant Pharmaceuticals Binge Eating Disorder Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Opiant Pharmaceuticals Binge Eating Disorder Drug Product Portfolio
- 4.4.5 Opiant Pharmaceuticals Recent Developments
- 4.5 Omeros Corp
- 4.5.1 Omeros Corp Company Information
- 4.5.2 Omeros Corp Business Overview
- 4.5.3 Omeros Corp Binge Eating Disorder Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Omeros Corp Binge Eating Disorder Drug Product Portfolio
- 4.5.5 Omeros Corp Recent Developments
- 4.6 Heptares
- 4.6.1 Heptares Company Information
- 4.6.2 Heptares Business Overview
- 4.6.3 Heptares Binge Eating Disorder Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Heptares Binge Eating Disorder Drug Product Portfolio
- 4.6.5 Heptares Recent Developments
- 4.7 Chronos Therapeutics
- 4.7.1 Chronos Therapeutics Company Information
- 4.7.2 Chronos Therapeutics Business Overview
- 4.7.3 Chronos Therapeutics Binge Eating Disorder Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Chronos Therapeutics Binge Eating Disorder Drug Product Portfolio
- 4.7.5 Chronos Therapeutics Recent Developments
5 Global Binge Eating Disorder Drug Market Scenario by Region
- 5.1 Global Binge Eating Disorder Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Binge Eating Disorder Drug Sales by Region: 2021-2032
- 5.2.1 Global Binge Eating Disorder Drug Sales by Region: 2021-2026
- 5.2.2 Global Binge Eating Disorder Drug Sales by Region: 2027-2032
- 5.3 Global Binge Eating Disorder Drug Revenue by Region: 2021-2032
- 5.3.1 Global Binge Eating Disorder Drug Revenue by Region: 2021-2026
- 5.3.2 Global Binge Eating Disorder Drug Revenue by Region: 2027-2032
- 5.4 North America Binge Eating Disorder Drug Market Facts & Figures by Country
- 5.4.1 North America Binge Eating Disorder Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Binge Eating Disorder Drug Sales by Country (2021-2032)
- 5.4.3 North America Binge Eating Disorder Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Binge Eating Disorder Drug Market Facts & Figures by Country
- 5.5.1 Europe Binge Eating Disorder Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Binge Eating Disorder Drug Sales by Country (2021-2032)
- 5.5.3 Europe Binge Eating Disorder Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Binge Eating Disorder Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Binge Eating Disorder Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Binge Eating Disorder Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Binge Eating Disorder Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Binge Eating Disorder Drug Market Facts & Figures by Country
- 5.7.1 South America Binge Eating Disorder Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Binge Eating Disorder Drug Sales by Country (2021-2032)
- 5.7.3 South America Binge Eating Disorder Drug Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Binge Eating Disorder Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Binge Eating Disorder Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Binge Eating Disorder Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Binge Eating Disorder Drug Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Binge Eating Disorder Drug Sales by Type (2021-2032)
- 6.1.1 Global Binge Eating Disorder Drug Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Binge Eating Disorder Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Binge Eating Disorder Drug Revenue by Type (2021-2032)
- 6.2.1 Global Binge Eating Disorder Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Binge Eating Disorder Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Binge Eating Disorder Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Binge Eating Disorder Drug Sales by Application (2021-2032)
- 7.1.1 Global Binge Eating Disorder Drug Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Binge Eating Disorder Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Binge Eating Disorder Drug Revenue by Application (2021-2032)
- 7.2.1 Global Binge Eating Disorder Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Binge Eating Disorder Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Binge Eating Disorder Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Binge Eating Disorder Drug Value Chain Analysis
- 8.1.1 Binge Eating Disorder Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Binge Eating Disorder Drug Production Mode & Process
- 8.2 Binge Eating Disorder Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Binge Eating Disorder Drug Distributors
- 8.2.3 Binge Eating Disorder Drug Customers
9 Global Binge Eating Disorder Drug Analyzing Market Dynamics
- 9.1 Binge Eating Disorder Drug Industry Trends
- 9.2 Binge Eating Disorder Drug Industry Drivers
- 9.3 Binge Eating Disorder Drug Industry Opportunities and Challenges
- 9.4 Binge Eating Disorder Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst